Ogluo

Ogluo is a medicine for treating severe hypoglycaemia (very low levels of glucose in the blood) in patients with diabetes who are at least 2 years old. Hypoglycaemia can occur when diabetes medicines to reduce blood glucose cause glucose levels to fall too low. In severe cases, patients can faint or become unconscious and they must be treated urgently to raise glucose levels. Ogluo contains the active substance glucagon. Ogluo is a ‘hybrid medicine’. This means that it is similar to a ‘reference medicine’ containing the same active substance. However, Ogluo is available as a solution for injection while the reference medicine is available as a powder that needs to be dissolved to make up the injection. The reference medicine for Ogluo is GlucaGen.